WallStreetZenWallStreetZen

NASDAQ: KTRA
Kintara Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Be the first to know when Wall Street analysts revise their KTRA stock forecasts and price targets.

Forecast return on equity

Is KTRA forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.16%

Forecast return on assets

Is KTRA forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

KTRA revenue forecast

What is KTRA's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$24.5M
Avg 2 year Forecast
$99.2M
Avg 3 year Forecast
$175.3M

KTRA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
KTRA$0.16N/AN/A
MYMD$2.81N/AN/A
AZTR$0.22N/AN/A
IBIO$1.72N/AN/A
CELZ$4.40N/AN/A
View Top Biotech Stocks

Kintara Therapeutics Stock Forecast FAQ

What is KTRA's revenue growth forecast for 2025-2027?

(NASDAQ: KTRA) Kintara Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.

Kintara Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast KTRA's revenue for 2025 to be $957,990,041, with the lowest KTRA revenue forecast at $957,990,041, and the highest KTRA revenue forecast at $957,990,041. On average, 1 Wall Street analysts forecast KTRA's revenue for 2026 to be $3,870,998,065, with the lowest KTRA revenue forecast at $3,870,998,065, and the highest KTRA revenue forecast at $3,870,998,065.

In 2027, KTRA is forecast to generate $6,841,782,179 in revenue, with the lowest revenue forecast at $6,841,782,179 and the highest revenue forecast at $6,841,782,179.

If you're new to stock investing, here's how to buy Kintara Therapeutics stock.

What is KTRA's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: KTRA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is KTRA's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: KTRA) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.